Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer

Overview of attention for article published in The Journal of Urology, July 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 85 X users

reddit: 2 Redditors
guideline: 3 clinical guideline sources

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 30 news stories from 30 outlets.

La chimiothérapie combinée peut être une alternative sûre et efficace pour le traitement des patients atteints d’un cancer de la vessie non invasif musculaire en cas de pénurie de BCG

Nouvelles du monde, 01 Mar 2023

Par le personnel de la poste ASCO Publié : 01/03/2023 10:58:00 Dernière mise à jour: 01/03/2023 11:20:01 Les chercheurs ont décou…

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer

Renal & Urology News, 26 Aug 2022

(HealthDay News) — Gemcitabine plus docetaxel (Gem/Doce) may be an alternative for the treatment of high-risk non-muscle-invasive…

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer

Cancer Therapy Advisor, 23 Aug 2022

(HealthDay News) — Gemcitabine plus docetaxel may be an alternative treatment for high-risk non-muscle-invasive bladder cancer (N…

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer

The Bismarck Tribune, 19 Aug 2022

FRIDAY, Aug. 19, 2022 (HealthDay News) -- Gemcitabine plus docetaxel (Gem/Doce) may be an alternative for the treatment of high-r…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 26 additional news stories.